TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1794242

Group type: EXPERIMENTAL
Intervention: Enoxacin tablets
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Enoxacin capsules
Number of subjects: 436

Group type: COMPARATOR
Intervention: Enoxacin
Number of subjects: 436

Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 436
Study: 10263521

Group type: EXPERIMENTAL
Intervention: Spanish-language prenatal health-education classes covering newborn care, labor and delivery, family planning, and dental health care.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (matched group of women who did not attend the classes).
Number of subjects: 0
Study: 2427144

Group type: EXPERIMENTAL
Intervention: Substance P (50 pmol)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Terfenadine (H1-receptor antagonist)
Number of subjects: 6
Study: 31340321

Group type: EXPERIMENTAL
Intervention: Lumbar oblique-pulling manipulation in combination with sling-exercise-therapy training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sling-exercise-therapy training
Number of subjects: 60
Study: 29273044

Group type: EXPERIMENTAL
Intervention: Exercise intervention (3 times/week for 16 weeks from 16-20 to 32-36 weeks' gestation)
Number of subjects: 639
Study: 26337246

Group type: EXPERIMENTAL
Intervention: Intravenous Tranexamic Acid (TXA) administered as a bolus dose of 15 mg/kg 10 minutes before tourniquet inflation and an infusion of 10 mg/kg/h for 3 hours post-operation
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intravenous Tranexamic Acid (TXA)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 105
Study: 23222500

Group type: EXPERIMENTAL
Intervention: Cancer cases (121,293 persons)
Number of subjects: 121293

Group type: COMPARATOR
Intervention: Matched noncancer control groups (522,839 persons)
Number of subjects: 121293
Study: 21644186

Group type: EXPERIMENTAL
Intervention: Brief strategic therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Minimal supportive therapy
Number of subjects: 120
Study: 18262853

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 16628330

Group type: EXPERIMENTAL
Intervention: Viabahn covered stents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare nitinol stents
Number of subjects: 0
Study: 15280841

Group type: EXPERIMENTAL
Intervention: 25 U of BTX‐A
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 50 U of BTX‐A
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 75 U of BTX‐A
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 11065206

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: 5-HT3-receptor antagonists
Number of subjects: 881

Group type: COMPARATOR
Intervention: Combination of droperidol and 5-HT3-receptor antagonists
Number of subjects: 881
Study: 9302301

Group type: EXPERIMENTAL
Intervention: 6.4 mg of zanamivir by intranasal spray plus 10 mg by inhalation
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: 10 mg of zanamivir by inhalation
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo by both routes
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Zanamivir groups (both inhaled and intranasal)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Zanamivir (inhaled and intranasal)
Number of subjects: 417
Study: 7508055

Group type: EXPERIMENTAL
Intervention: Indapamide (IND, 2.5 mg/day)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ, 25 mg/day)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Nifedipine (NFD, 40 mg/day)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Enalapril (ENL, 20 mg/day)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Atenolol (ATL, 100 mg/day)
Number of subjects: 151
Study: 2834478

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin, fragmine (5,000 anti‐Xa U/24 h)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard heparin, calciparin (5,000 IU/8 h)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (fragmine and calciparin)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin, fragmine
Number of subjects: 50
Study: 29249436

Group type: EXPERIMENTAL
Intervention: PROMISE minimal-risk tool
Number of subjects: 1764

Group type: EXPERIMENTAL
Intervention: PROMISE minimal-risk tool (re-estimated covariate coefficients)
Number of subjects: 1764
Study: 27110893

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 24 U in crow's feet lines
Number of subjects: 1362
Study: 25401967

Group type: EXPERIMENTAL
Intervention: Equistasi group (wearing active device)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inactive device group (control)
Number of subjects: 40
Study: 23545929

Group type: EXPERIMENTAL
Intervention: 3 new skin brightener formulations containing SMA‐432
Number of subjects: 68

Group type: COMPARATOR
Intervention: 4% hydroquinone (HQ)
Number of subjects: 68
Study: 20685748

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg
Number of subjects: 6184

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg
Number of subjects: 6184

Group type: EXPERIMENTAL
Intervention: Salmeterol plus Fluticasone propionate (SFC)
Number of subjects: 6184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6184
Study: 18647093

Group type: COMPARATOR
Intervention: Transcutaneous irradiation with polychromatic visible polarized light (540‐780 nm; 68% polarization; power density 3.0 E‐10 W/cm(2)) for 28 consecutive days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 16984739

Group type: EXPERIMENTAL
Intervention: Pycnogenol (1 mg/kg body weight/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pycnogenol
Number of subjects: 0
Study: 14559692

Group type: EXPERIMENTAL
Intervention: Modified FLAG regimen (n=10): Fludarabine (50 mg/d, VDx5 d) and Ara‐C (200 mg/d, VDx5 or 7 d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Classic FLAG regimen (n=6): Fludarabine (50 mg/d, VDx5d), Ara‐C (500 or 1,000 mg/d, VDx5d) and G‐CSF (300 microg/d, x5 d)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Modified FLAG regimen (n=10)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Classic FLAG regimen (n=6)
Number of subjects: 16
Study: 10691817

Group type: EXPERIMENTAL
Intervention: Oxybutynin with salivary stimulant pastilles
Number of subjects: 67

Group type: COMPARATOR
Intervention: Oxybutynin alone
Number of subjects: 67
Study: 9076201

Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-patching
Number of subjects: 46
Study: 8408860

Group type: EXPERIMENTAL
Intervention: Assisted self‐directed learning (ASD)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Traditional lecture methods (TLM)
Number of subjects: 19
Study: 2951131

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 24
Study: 31268466

Group type: EXPERIMENTAL
Intervention: Nonculprit instantaneous wave‐free ratio
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Resting distal pressure/aortic pressure
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Coronary flow reserve
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Hyperemic index of microcirculatory resistance
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Resting microcirculatory resistance
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Distal pressure from rest to hyperemia
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Resistive reserve ratio
Number of subjects: 73
Study: 28104251

Group type: EXPERIMENTAL
Intervention: Natalizumab 300mg every 4 weeks
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 24393627

Group type: EXPERIMENTAL
Intervention: Oral Health Program (OHP) participation (G1)
Number of subjects: 194

Group type: COMPARATOR
Intervention: No Oral Health Program participation (G2)
Number of subjects: 194
Study: 23078527

Group type: EXPERIMENTAL
Intervention: TACR1 SNPs (rs3771863, rs3755459, rs1106855)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: TACR1 SNP rs3771863
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: TACR1 SNPs
Number of subjects: 326
Study: 21705063

Group type: EXPERIMENTAL
Intervention: Intensive treatment of multiple cardiovascular risk factors
Number of subjects: 3057

Group type: COMPARATOR
Intervention: Routine care of diabetes
Number of subjects: 3057
Study: 19317704

Group type: EXPERIMENTAL
Intervention: PAULA the PAIN-METER
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard VAS
Number of subjects: 48
Study: 16530576

Group type: EXPERIMENTAL
Intervention: Oral melphalan and prednisone plus thalidomide (MPT)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Oral melphalan and prednisone (MP) alone
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Enoxaparin prophylaxis
Number of subjects: 255
Study: 12767550

Group type: EXPERIMENTAL
Intervention: 0.3 mg conjugated equine estrogens (CEE)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogens (CEE)
Number of subjects: 25
Study: 10696890

Group type: EXPERIMENTAL
Intervention: 0.2 percent glyceryl trinitrate ointment
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 10182389

Group type: EXPERIMENTAL
Intervention: Geriatric evaluation and management (GEM)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual primary care (UPC)
Number of subjects: 160
Study: 8334330

Group type: EXPERIMENTAL
Intervention: 10 mg ganciclovir/kg 3 times a week (group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 6 mg ganciclovir/kg once daily for 5 days a week (group B)
Number of subjects: 28
Study: 2869077

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 27
Study: 29449292

Group type: EXPERIMENTAL
Intervention: Healthy Eating Lifestyle Programme (HELP) - 12 one‐to‐one sessions across 6 months
Number of subjects: 174

Group type: COMPARATOR
Intervention: Enhanced standard care - single 1‐hour one‐to‐one nurse‐delivered session
Number of subjects: 174
Study: 27394144

Group type: EXPERIMENTAL
Intervention: Knot-tying suture technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Knotless suture anchor technique
Number of subjects: 40
Study: 23359781

Group type: EXPERIMENTAL
Intervention: isoosmolar nonionic dimer contrast medium
Number of subjects: 38

Group type: COMPARATOR
Intervention: low-osmolar nonionic monomer contrast medium
Number of subjects: 38
Study: 22092271

Group type: COMPARATOR
Intervention: Low-fat meal, no exercise
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-fat meal, postprandial exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-fat meal, no exercise
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-fat meal, postprandial exercise
Number of subjects: 40
Study: 21186923

Group type: EXPERIMENTAL
Intervention: 200 mg of modafinil (once daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (modafinil and placebo)
Number of subjects: 20
Study: 16934861

Group type: EXPERIMENTAL
Intervention: Party drug use (alcohol, cannabis, ecstasy, cocaine)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Patterns of substance use
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Psychological and social problems related to party drug use
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Receptiveness to harm reduction measures
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Need for prevention personnel
Number of subjects: 302
Study: 15868347

Group type: EXPERIMENTAL
Intervention: Residential group living environment
Number of subjects: 12
Study: 12063485

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 15
Study: 10218040

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS)-free dentifrice
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sodium lauryl sulfate (SLS) dentifrice
Number of subjects: 47
Study: 9430602

Group type: EXPERIMENTAL
Intervention: Globin digest 1 g
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Globin digest 4 g
Number of subjects: 22
Study: 1907551

Group type: EXPERIMENTAL
Intervention: Insulin‐induced hypoglycaemia with concomitant alpha‐adrenoceptor blockade
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Insulin‐induced hypoglycaemia with total autonomic blockade (alpha‐adrenoceptor blockade combined with beta‐adrenoceptor blockade and atropine)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Insulin‐induced hypoglycaemia without any autonomic blockade
Number of subjects: 7
Study: 7166137

Group type: EXPERIMENTAL
Intervention: Methadone maintenance
Number of subjects: 556

Group type: COMPARATOR
Intervention: Street heroin
Number of subjects: 556
Study: 30659410

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risedronate 35 mg weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study: 28637881

Group type: EXPERIMENTAL
Intervention: Ideal baseline physical activity
Number of subjects: 1751

Group type: COMPARATOR
Intervention: Intermediate baseline physical activity
Number of subjects: 1751

Group type: COMPARATOR
Intervention: Poor baseline physical activity
Number of subjects: 1751
Study: 24215227

Group type: EXPERIMENTAL
Intervention: Culturally adapted motivational interviewing
Number of subjects: 57

Group type: COMPARATOR
Intervention: Unadapted motivational interviewing
Number of subjects: 57
Study: 21554143

Group type: EXPERIMENTAL
Intervention: Alendronate plus alfacalcidol (combination therapy)
Number of subjects: 2164

Group type: COMPARATOR
Intervention: Alendronate alone (monotherapy)
Number of subjects: 2164
Study: 19994693

Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiguan (PC 6)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (tape covering without acupuncture)
Number of subjects: 100
Study: 17237735

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) use
Number of subjects: 202638

Group type: EXPERIMENTAL
Intervention: Current users of HT
Number of subjects: 202638
Study: 15017896

Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m2 plus Gemcitabine 1250 mg/m2, day first, and Gemcitabine 1250 mg/m2, day 8, every 3 weeks, total 3 cycles plus fractionated radiation therapy (40-46 Gy) for stage IIIa (N2) and IIIb patients.
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m2 plus Gemcitabine 1250 mg/m2, every three weeks, total 4 cycles without fractionated radiation therapy for stage IV patients.
Number of subjects: 88
Study: 11698931

Group type: EXPERIMENTAL
Intervention: Probiotic therapy; specific strains not mentioned, dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; no specific control intervention mentioned.
Number of subjects: 0
Study: 9812566

Group type: EXPERIMENTAL
Intervention: Purified human leucocytic interferon-alpha
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study: 8131152

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adinazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fenfluramine
Number of subjects: 0
Study: 2887304

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29405540

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 14671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14671

Group type: EXPERIMENTAL
Intervention: Sitagliptin with Acarbose
Number of subjects: 14671
Study: 27859588

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Client-centered therapy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy and Client-centered therapy
Number of subjects: 61
Study: 24947717

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy at discharge (n = 6,873)
Number of subjects: 8510

Group type: COMPARATOR
Intervention: No-beta-blocker therapy at discharge (n = 1,637)
Number of subjects: 8510

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy after propensity-score matching (n = 1,325)
Number of subjects: 8510
Study: 22737708

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal aerosol at 320 μg once daily for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal aerosol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20236696

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 18195071

Group type: EXPERIMENTAL
Intervention: DNA C plus NYVAC C
Number of subjects: 40

Group type: COMPARATOR
Intervention: NYVAC C alone
Number of subjects: 40
Study: 15718059

Group type: EXPERIMENTAL
Intervention: STX plus attendance contracting and prompting (CP)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard treatment (STX)
Number of subjects: 102
Study: 12766100

Group type: EXPERIMENTAL
Intervention: Healthy food choices meal plan (HFC)
Number of subjects: 648

Group type: COMPARATOR
Intervention: Exchange-based meal plan (EXCH)
Number of subjects: 648
Study: 10561182

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (vincristine, dactinomycin, cyclophosphamide, doxorubicin)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Overall (all patients)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Grade 3 lesion
Number of subjects: 81
Study: 8686827

Group type: EXPERIMENTAL
Intervention: One-handed cricoid pressure
Number of subjects: 120

Group type: COMPARATOR
Intervention: Two-handed cricoid pressure
Number of subjects: 120
Study: 1909607

Group type: EXPERIMENTAL
Intervention: Ritanserin (RTS)
Number of subjects: 0
Study: 6373482

Group type: EXPERIMENTAL
Intervention: Nova-T
Number of subjects: 1865

Group type: COMPARATOR
Intervention: copper-T-200
Number of subjects: 1865
Study: 31573928

Group type: EXPERIMENTAL
Intervention: On-site support
Number of subjects: 194

Group type: COMPARATOR
Intervention: Remote support
Number of subjects: 194
Study: 30630790

Group type: EXPERIMENTAL
Intervention: Yousiyue (Drospirenone and Ethinylestradiol tablets) plus comprehensive nursing intervention program
Number of subjects: 150

Group type: COMPARATOR
Intervention: General routine nursing and treatment (Control)
Number of subjects: 150
Study: 25689059

Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Group exercise
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 76
Study: 24798080

Group type: EXPERIMENTAL
Intervention: Dietary advice and physical activity intervention
Number of subjects: 117
Study: 21917733

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (IVC)
Number of subjects: 60
Study: 21108390

Group type: EXPERIMENTAL
Intervention: Donepezil (2.5-10 mg/day)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 16973667

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily for 10 weeks (groups 1 and 2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (group 3)
Number of subjects: 45
Study: 15877268

Group type: EXPERIMENTAL
Intervention: Direct wrist arthro MRI
Number of subjects: 125
Study: 11871208

Group type: EXPERIMENTAL
Intervention: Multifaceted professional interventions
Number of subjects: 48000

Group type: EXPERIMENTAL
Intervention: Organisational interventions (e.g., central computerised tracking systems, nurses contacting patients)
Number of subjects: 48000

Group type: EXPERIMENTAL
Intervention: Patient education added to professional and organisational interventions
Number of subjects: 48000

Group type: EXPERIMENTAL
Intervention: Enhanced role of nurses in patient-oriented interventions
Number of subjects: 48000
Study: 11245034

Group type: EXPERIMENTAL
Intervention: Intracarotid infusion of papaverine and BCNU (250 mg)
Number of subjects: 155
Study: 7698589

Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg daily)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 2693114

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0
Study: 1070142

Group type: EXPERIMENTAL
Intervention: Oxytetracycline
Number of subjects: 58

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 58
Study: 31081656

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 126
Study: 31625252

Group type: EXPERIMENTAL
Intervention: Haemorrhoid energy therapy (HET)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rubber band ligation (RBL)
Number of subjects: 30
Study: 26319710

Group type: EXPERIMENTAL
Intervention: couple-based HIV counseling and testing (HIV-CT) intervention
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: relationship-focused HIV counseling and testing (HIV-CT) intervention
Number of subjects: 330

Group type: COMPARATOR
Intervention: standard individual HIV counseling and testing (HIV-CT)
Number of subjects: 330
Study: 26493786

Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 23540599

Group type: EXPERIMENTAL
Intervention: Traumatic video
Number of subjects: 10

Group type: COMPARATOR
Intervention: Neutral video
Number of subjects: 10
Study: 21635995

Group type: EXPERIMENTAL
Intervention: Test formulation (levodopa 200 mg/benserazide 50 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation (branded formulation)
Number of subjects: 24
Study: 19494555

Group type: EXPERIMENTAL
Intervention: Fetal monitoring with cardiotocography during labor
Number of subjects: 0
Study: 16542275

Group type: EXPERIMENTAL
Intervention: EndoCinch
Number of subjects: 51

Group type: COMPARATOR
Intervention: Enteryx
Number of subjects: 51
Study: 12616141

Group type: EXPERIMENTAL
Intervention: Suppressive valacyclovir therapy
Number of subjects: 225